Changes in neurohormonal gut peptides following bariatric surgery

International Journal of Obesity

Volumn 35, Issue 2, 2011, Pages 153-166

  Ochner, C N ^a   Gibson, C ^a   Shanik, M ^b   Goel, V ^a   Geliebter, A ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b Northwell Health   (United States)

Author keywords

brain; ghrelin; GLP 1; hormone; PYY; RYGB

Indexed keywords

GASTROINTESTINAL HORMONE; GHRELIN; NEUROHORMONE;

APPETITE; BARIATRIC SURGERY; BODY WEIGHT; CALORIC INTAKE; PRIORITY JOURNAL; REVIEW; STOMACH BYPASS; WEIGHT REDUCTION;

APPETITE REGULATION; BODY WEIGHT; FEMALE; GASTRIC BYPASS; GASTROINTESTINAL HORMONES; GHRELIN; HUMANS; MALE; NEUROTRANSMITTER AGENTS; OBESITY, MORBID;

EID: 79951681579     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.132     Document Type: Review

References (201)

1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.
2. Lenard NR, Berthoud HR. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver Spring) 2008; 16 (Suppl 3): S11-S22.
3. Berthoud HR, Morrison C. The brain, appetite, and obesity Annu Rev Psychol 2008; 59: 55-92.
4. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C et al. Resistin, adiponectin, ghrelin, leptin, and proinflamma-tory cytokines: relationships in obesity. Obes Res 2004; 12: 962-971.
5. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737. (Pubitemid 39346675)
6. Brolin RE, LaMarca LB, Kenler HA, Cody RP. Malabsorptive gastric bypass in patients with superobesity. J Gastrointest Surg 2002; 6: 195-203;discussion 204-5.
7. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89: 2608-2615. (Pubitemid 38766339)
8. Tadross JA, le Roux CW. The mechanisms of weight loss after bariatric surgery. Int J Obes (London) 2009; 33 (Suppl 1): S28-S32.
9. Orlando FA, Goncalves CG, George ZM, Halverson JD, Cunningham PR, Meguid MM. Neurohormonal pathways regulating food intake and changes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1: 486-495.
10. Doucet E, Cameron J. Appetite control after weight loss: what is the role of bloodborne peptides? Appl Physiol Nutr Metab 2007; 32: 523-532.
11. Batterham RL, Ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 2007; 450: 106-109. (Pubitemid 350070563)
12. Balsiger BM, Poggio JL, Mai J, Kelly KA, Sarr MG. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. J Gastrointest Surg 2000; 4: 598-605.
13. Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. Eur J Endocrinol 2008; 158: 135-145. (Pubitemid 351298529)
14. Marceau P, Hould FS, Simard S, Lebel S, Bourque RA, Potvin M et al. Biliopancreatic diversion with duodenal switch. World J Surg 1998; 22: 947-954. (Pubitemid 28374612)
15. Poves I, Cabrera M, Maristany C, Coma A, Ballesta-Lopez C. Gastrointestinal quality of life after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2006; 16: 19-23. (Pubitemid 43232234)
16. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007; 132: 2116-2130. (Pubitemid 46693747)
17. Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity\a review. Neuropeptides 2006; 40: 375-401. (Pubitemid 44773748)
18. Geliebter A. Gastric distension and gastric capacity in relation to food intake in humans. Physiol Behav 1988; 44: 665-668. (Pubitemid 19030132)
19. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin\a hormone with multiple functions. Front Neuroendo-crinol 2004; 25: 27-68.
20. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008; 18: 158-168. (Pubitemid 351282471)
21. Olszewski PK, Li D, Grace MK, Billington CJ, Kotz CM, Levine AS. Neural basis of orexigenic effects of ghrelin acting within lateral hypothalamus. Peptides 2003; 24: 597-602. (Pubitemid 36829349)
22. Bloomgarden ZT. Gut hormones, obesity, polycystic ovarian syndrome, malignancy, and lipodystrophy syndromes. Diabetes Care 2007; 30: 1934-1939. (Pubitemid 47036385)
23. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
24. Nonogaki K. Ghrelin and feedback systems. Vitam Horm 2008; 77: 149-170.
25. Garcia-Unzueta MT, Fernandez-Santiago R, Dominguez-Diez A, Vazquez-Salvi L, Fernandez-Escalante JC, Amado JA. Fasting plasma ghrelin levels increase progressively after biliopancreatic diversion: one-year follow-up. Obes Surg 2005; 15: 187-190. (Pubitemid 40316001)
26. Geloneze B, Tambascia MA, Pilla VF, Geloneze SR, Repetto EM, Pareja JC. Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. Obes Surg 2003; 13: 17-22. (Pubitemid 36250233)
27. Bohdjalian A, Langer FB, Shakeri-Leidenmuhler S, Gfrerer L, Ludvik B, Zacherl J et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg 2010; 20: 535-540.
28. Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl Eet al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 2005; 15: 1024-1029. (Pubitemid 41116888)
29. Depaula AL, Macedo AL, Schraibman V, Mota BR, Vencio S. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. Surg Endosc 2008; 23: 1724-1732.
30. Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospec-tive randomized trial. Ann Surg 2009; 250: 234-241.
31. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247: 401-407.
32. Schindler K, Prager G, Ballaban T, Kretschmer S, Riener R, Buranyi B et al. Impact of laparoscopic adjustable gastric banding on plasma ghrelin, eating behaviour and body weight. Eur J Clin Invest 2004; 34: 549-554. (Pubitemid 39120224)
33. Uzzan B, Catheline JM, Lagorce C, Airinei G, Bon C, Cohen R et al. Expression of ghrelin in fundus is increased after gastric banding in morbidly obese patients. Obes Surg 2007; 17: 1159-1164. (Pubitemid 351321321)
34. Nijhuis J, van Dielen FM, Buurman WA, Greve JW. Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. Obes Surg 2004; 14: 783-787. (Pubitemid 38982263)
35. Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 2004; 12: 346-350. (Pubitemid 41132559)
36. Foschi D, Corsi F, Rizzi A, Asti E, Carsenzuola V, Vago T et al. Vertical banded gastroplasty modifies plasma ghrelin secretion in obese patients. Obes Surg 2005; 15: 1129-1132. (Pubitemid 41390209)
37. Kotidis EV, Koliakos GG, Baltzopoulos VG, Ioannidis KN, Yovos JG, Papavramidis ST. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment\a prospective study. Obes Surg 2006; 16: 1425-1432. (Pubitemid 44759973)
38. Foschi D, Corsi F, Colombo F, Vago T, Bevilaqua M, Rizzi A et al. Different effects of vertical banded gastroplasty and Roux-en-Y gastric bypass on meal inhibition of ghrelin secretion in morbidly obese patients. J Invest Surg 2008; 21: 77-81. (Pubitemid 351404804)
39. Shak JR, Roper J, Perez-Perez GI, Tseng CH, Francois F, Gamagaris Z et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg 2008; 18: 1089-1096.
40. Ram E, Vishne T, Diker D, Gal-Ad I, Maayan R, Lerner I et al. Impact of gastric banding on plasma ghrelin, growth hormone, cortisol, DHEA and DHEA-S levels. Obes Surg 2005; 15: 1118-1123. (Pubitemid 41390207)
41. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (London) 2009; 33: 786-795.
42. Garcia de la Torre N, Rubio MA, Bordiu E, Cabrerizo L, Aparicio E, Hernandez C et al. Effects ofweight loss afterbariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 2008; 93: 4276-4281. (Pubitemid 352789522)
43. Lin E, Gletsu N, Fugate K, McClusky D, Gu LH, Zhu JL et al. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg 2004; 139: 780-784. (Pubitemid 38886515)
44. Fruhbeck G, Diez-Caballero A, Gil MJ, Montero I, Gomez-Ambrosi J, Salvador J et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 2004; 14: 606-612. (Pubitemid 38716579)
45. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006; 14: 1553-1561. (Pubitemid 46214822)
46. Fruhbeck G, Rotellar F, Hernandez-Lizoain JL, Gil MJ, Gomez-Ambrosi J, Salvador J et al. Fasting plasma ghrelin concentra-tions 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg 2004; 14: 1208-1215. (Pubitemid 39458595)
47. Morinigo R, Casamitjana R, Moize V, Lacy AM, Delgado S, Gomis R et al. Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res 2004; 12: 1108-1116. (Pubitemid 41132490)
48. Sundbom M, Holdstock C, Engstrom BE, Karlsson FA. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg 2007; 17: 304-310. (Pubitemid 46659288)
49. Pardina E, Lopez-Tejero MD, Llamas R, Catalan R, Galard R, Allende H et al. Ghrelin and apolipoprotein AIV levels show opposite trends to leptin levels during weight loss in morbidly obese patients. Obes Surg 2009; 19: 1414-1423.
50. Garcia-Fuentes E, Garrido-Sanchez L, Garcia-Almeida JM, Garcia-Arnes J, Gallego-Perales JL, Rivas-Marin J et al. Different effect of laparoscopic Roux-en-Y gastric bypass and open biliopancreatic diversion of Scopinaro on serum PYY and ghrelin levels. Obes Surg 2008; 18: 1424-1429.
51. Bose M, Machineni S, Olivan B, Teixeira J, McGinty JJ, Bawa B et al. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring) 2010; 18: 1085-1091.
52. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630. (Pubitemid 34755670)
53. Tritos NA, Mun E, Bertkau A, Grayson R, Maratos-Flier E, Goldfine A. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 2003; 11: 919-924. (Pubitemid 41137501)
54. Fruhbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 2004; 350: 308-309. (Pubitemid 38067650)
55. Chan JL, Mun EC, Stoyneva V, Mantzoros CS, Goldfine AB. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 2006; 14: 194-198. (Pubitemid 46214749)
56. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008; 16: 298-305. (Pubitemid 351271908)
57. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006; 93: 210-215. (Pubitemid 43259607)
58. Adami GF, Cordera R, Marinari G, Lamerini G, Andraghetti G, Scopinaro N. Plasma ghrelin concentratin in the short-term following biliopancreatic diversion. Obes Surg 2003; 13: 889-892. (Pubitemid 38010710)
59. Adami GF, Cordera R, Andraghetti G, Camerini GB, Marinari GM, Scopinaro N. Changes in serum ghrelin concentration following biliopancreatic diversion for obesity. Obes Res 2004; 12: 684-687. (Pubitemid 41132512)
60. Valera Mora ME, Manco M, Capristo E, Guidone C, Iaconelli A, Gniuli D et al. Growth hormone and ghrelin secretion in severely obese women before and after bariatric surgery. Obesity (Silver Spring) 2007; 15: 2012-2018. (Pubitemid 47402233)
61. Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88: 3177-3183. (Pubitemid 36877491)
62. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-1602. (Pubitemid 36623375)
63. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 2002; 8: 643-644. (Pubitemid 34778697)
64. Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009; 150: 2518-2525.
65. le Roux CW, Neary NM, Halsey TJ, Small CJ, Martinez-Isla AM, Ghatei MA et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 2005; 90: 4521-4524. (Pubitemid 41159336)
66. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002; 123: 1120-1128.
67. Williams DL, Grill HJ, Cummings DE, Kaplan JM. Vagotomy dissociates short-and long-term controls of circulating ghrelin. Endocrinology 2003; 144: 5184-5187. (Pubitemid 37476045)
68. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988.
69. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141: 4255-4261.
70. Hosoda H, Kojima M, Matsuo H, Kangawa K Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastro-intestinal tissue. Biochem Biophys Res Commun 2000; 279: 909-913. (Pubitemid 32042875)
71. Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005; 54: 18-24. (Pubitemid 40007213)
72. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004; 89: 3062-3065. (Pubitemid 38766409)
73. Gauna C, Delhanty PJ, Hofland LJ,Janssen JA, Broglio F, Ross RJ et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 2005; 90: 1055-1060. (Pubitemid 40279233)
74. Weickert MO, Loeffelholz CV, Arafat AM, Schofl C, Otto B, Spranger J et al. Euglycemic hyperinsulinemia differentially modulates circulating total and acylated-ghrelin in humans. J Endocrinol Invest 2008; 31: 119-124. (Pubitemid 351596971)
75. Holmes E, Davies I, Lowe G, Ranganath LR. Circulating ghrelin exists in both lipoprotein bound and free forms. Ann Clin Biochem 2009; 46: 514-516.
76. Weickert MO, Spranger J, Holst JJ, Otto B, Koebnick C, Mohlig M et al. Wheat-fibre-induced changes of postprandial peptide YY and ghrelin responses are not associated with acute alterations of satiety. Br J Nutr 2006; 96: 795-798. (Pubitemid 46454553)
77. Lomenick JP, Melguizo MS, Mitchell SL, Summar ML, Anderson JW. Effects of meals high in carbohydrate, protein, and fat on ghrelin and peptide YY secretion in prepubertal children. J Clin Endocrinol Metab 2009; 94: 4463-4471.
78. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
79. Ballantyne GH. Peptide YY (1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg 2006; 16: 651-658.
80. Unniappan S, McIntosh CH, Demuth HU, Heiser U, Wolf R, Kieffer TJ. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia 2006; 49: 1915-1923. (Pubitemid 44025047)
81. Chelikani PK, Haver AC, Reidelberger RD. Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1064-R1070. (Pubitemid 39391050)
82. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007; 292: E1062-E1068. (Pubitemid 46536505)
83. Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 2003; 311: 915-919. (Pubitemid 37393405)
84. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948. (Pubitemid 37064767)
85. le Roux CW, Bloom SR. Peptide YY, appetite and food intake. Proc Nutr Soc 2005; 64: 213-216.
86. Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Tatemoto K et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985; 89: 494-499. (Pubitemid 15239150)
87. Lin HC, Chey WY. Cholecystokinin and peptide YYare released by fat in either proximal or distal small intestine in dogs. Regul Pept 2003; 114: 131-135. (Pubitemid 36773877)
88. Pfluger PT, Kampe J, Castaneda TR, Vahl T, D'Alessio DA, Kruthaupt T et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 2007; 92: 583-588.
89. Wynne K, Bloom SR. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab 2006; 2: 612-620. (Pubitemid 44691297)
90. Reinehr T, Roth CL, Schernthaner GH, Kopp HP, Kriwanek S, Schernthaner G. Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically induced weightloss. Obes Surg 2007; 17: 1571-1577.
91. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, Cabrerizo L et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002; 12: 324-327. (Pubitemid 34621023)
92. Valderas JP, Irribarra V, Boza C, de la Cruz R, Liberona Y, Acosta AM et al. Medical and surgical treatments for obesity have opposite effects on peptide YYand appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab 2010; 95: 1069-1075.
93. Le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-114. (Pubitemid 43054062)
94. Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91: 1735-1740.
95. Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90: 359-365. (Pubitemid 40116682)
96. Riediger T, Bothe C, Becskei C, Lutz TA. Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology 2004; 79: 317-326. (Pubitemid 39179161)
97. Holst JJ. The physiology ofglucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
98. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 2001; 25 (Suppl 5): S42-S47. (Pubitemid 34146322)
99. Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004; 91: 439-446. (Pubitemid 38386908)
100. Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety\effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001; 25: 1206-1214. (Pubitemid 32721544)
101. Valverde I, Puente J, Martin-Duce A, Molina L, Lozano O, Sancho V et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg 2005; 15: 387-397. (Pubitemid 40463608)
102. Morinigo R, Vidal J, Lacy AM, Delgado S, Casamitjana R, Gomis R. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg 2008; 247: 270-275. (Pubitemid 351156769)
103. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780-785. (Pubitemid 350035654)
104. Bose M, Olivan B, Teixeira J, Pi-Sunyer FX, Laferrère B. Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes Surg 2009; 19: 217-229.
105. Baldinger M, Rubin R, Wright N, Flancbaum A, Geliebter A. Change in hunger, fullness, ghrelin, PYYand GLP-1 in relation to a fixed test meal pre and post Rou-en-Y gastric bypass (RYGBS). Appetite 2007; 49: 277 (abstract).
106. de Carvalho CP, Marin DM, de Souza AL, Pareja JC, Chaim EA, de Barros Mazon S et al. GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg 2009; 19: 313-320.
107. Chandra R, Liddle RA. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes 2007; 14: 63-67. (Pubitemid 46375391)
108. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contrac-tion. J Clin Invest 1985; 75: 1144-1152. (Pubitemid 15087139)
109. Suzuki S, Ramos EJ, Goncalves CG, Chen C, Meguid MM. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005; 138: 283-290.
110. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem 1998; 44: 991-1001. (Pubitemid 28213139)
111. Kellum JM, Kuemmerle JF, O'Dorisio TM, Rayford P, Martin D, Engle K et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990; 211: 763-770;discussion 770-1.
112. Foschi D, Corsi F, Pisoni L, Vago T, Bevilacqua M, Asti E et al. Plasma cholecystokinin levels after vertical banded gastroplasty: effects of an acidified meal. Obes Surg 2004; 14: 644-647. (Pubitemid 38716585)
113. Konturek JW. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori. J Physiol Pharmacol 1994; 45 (4 Suppl 1): 3-66.
114. Katsusuke S, Takeuchi T, Watanabe S, Nishiwaki H. Postprandial plasma cholecystokinin response in patients after gastrectomy and pancreatoduodenectomy Am J Gastroenterol 2008; 81: 1038-1042.
115. Baskin DG, Figlewicz Lattemann D, Seeley RJ, Woods SC, Porte Jr D, Schwartz MW. Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight. Brain Res 1999; 848: 114-123. (Pubitemid 30001660)
116. Wang L, Barachina MD, Martinez V, Wei JY, Tache Y Synergistic interaction between CCK and leptin to regulate food intake. Regul Pept 2000; 92: 79-85.
117. Chi MM, Fan G, Fox EA. Increased short-term food satiation and sensitivity to cholecystokinin in neurotrophin-4 knock-in mice. Am JPhysiol Regul Integr Comp Physiol 2004; 287: R1044-R1053. (Pubitemid 39391048)
118. Barrachina MD, Martinez V, Wang L, Wei JY, Tache Y Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci USA 1997; 94: 10455-10460. (Pubitemid 27407063)
119. Weickert MO, Mohlig M, Spranger J, Schofl C, Loeffelholz CV, Riepl RL et al. Effects of euglycemic hyperinsulinemia and lipid infusion on circulating cholecystokinin. J Clin Endocrinol Metab 2008; 93: 2328-2333. (Pubitemid 351831555)
120. Woods SC, D'Alessio DA. Central control of body weight and appetite. J Clin Endocrinol Metab 2008; 93 (11 Suppl 1): S37-S50.
121. Wang MY, Lee Y, Unger RH. Novel form of lipolysis induced by leptin. J Biol Chem 1999; 274: 17541-17544.
122. Fried SK, Ricci MR, Russell CD, Laferrère B. Regulation of leptin production in humans. J Nutr 2000; 130: 3127S-3131S. (Pubitemid 32005354)
123. Hukshorn CJ, van Dielen FM, Buurman WA, Westerterp-Plantenga MS, Campfield LA, Saris WH. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 2002; 26: 504-509. (Pubitemid 34407263)
124. Cammisotto PG, Bendayan M. Leptin secretion by white adipose tissue and gastric mucosa. Histol Histopathol 2007; 22: 199-210. (Pubitemid 46117106)
125. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581.
126. DePaula AL, Macedo AL, Schraibman V, Mota BR, Vencio S. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. Surg Endosc 2009; 23: 1724-1732.
127. Pardina E, Lopez-Tejero MD, Llamas R, Catalan R, Galard R, Allende H et al. Ghrelin and apolipoprotein AIV levels show opposite trends to leptin levels during weight loss in morbidly obese patients. Obes Surg 2009; 19: 1414-1423.
128. Trakhtenbroit MA, Leichman JG, Algahim MF, Miller III CC, Moody FG, Lux TR et al. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med 2009; 122: 435-442.
129. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240: 236-242. (Pubitemid 38963013)
130. Kotidis EV, Koliakos G, Papavramidis TS, Papavramidis ST The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? Obes Surg 2006; 16: 554-559. (Pubitemid 43786076)
131. Foschi D, Corsi F, Pisoni L, Vago T, Bevilacqua M, Trabucchi A et al. Plasma leptin levels after vertical banded gastroplasty for morbid obesity: effects of an acidified meal. Obes Surg 2003; 13: 874-878. (Pubitemid 38010708)
132. Boozer CN, Leibel RL, Love RJ, Cha MC, Aronne LJ. Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism 2001; 50: 889-893. (Pubitemid 32755004)
133. Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest 2008; 118: 2583-2591. (Pubitemid 351949785)
134. Maffeis C, Manfredi R, Trombetta M, Sordelli S, Storti M, Benuzzi T et al. Insulin sensitivity is correlated with subcutaneous but not visceral body fat in overweight and obese prepubertal children. J Clin Endocrinol Metab 2008; 93: 2122-2128. (Pubitemid 351831525)
135. Bjorntorp P. Obesity, atherosclerosis and diabetes mellitus. Verh Dtsch Ges Inn Med 1987; 93: 443-448.
136. Rushing PA, Lutz TA, Seeley RJ, Woods SC. Amylin and insulin interact to reduce food intake in rats. Horm Metab Res 2000; 32: 62-65. (Pubitemid 30143610)
137. Ballantyne GH, Farkas D, Laker S, Wasielewski A. Short-term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass. Obes Surg 2006; 16: 1189-1197. (Pubitemid 44433156)
138. Dixon AF, Dixon JB, O'Brien PE. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 2005; 90: 813-819. (Pubitemid 40279202)
139. Lee WJ, Lee YC, Ser KH, Chen JC, Chen SC. Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. Obes Surg 2008; 18: 1119-1125.
140. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006; 55: 2025-2031. (Pubitemid 44509976)
141. Morrow J, Gluck M, Lorence M, Flancbaum L, Geliebter A. Night eating status and influence on body weight, body image, hunger, and cortisol pre-and post-Roux-en-Y Gastric Bypass (RYGB) surgery. Eat Weight Disord 2008; 13: e96-e99.
142. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-639. (Pubitemid 30183753)
143. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003; 124: 1325-1336. (Pubitemid 36531807)
144. Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH, Bell JD et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun 2006; 350: 298-306. (Pubitemid 44515085)
145. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529. (Pubitemid 38667912)
146. Tovar S, Nogueiras R, Tung LY, Castaneda TR, Vazquez MJ, Morris A et al. Central administration of resistin promotes short-term satiety in rats. Eur J Endocrinol 2005; 153: R1-R5. (Pubitemid 41410504)
147. Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets 2005; 6: 181-189. (Pubitemid 40394313)
148. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, Barnes AJ. Distribution and release of human pancreatic polypeptide. Gut 1976; 17: 940-944. (Pubitemid 8027537)
149. Schrumpf E, Bergan A, Djoseland O, Fausa O, Flaten O, Skagen DW et al. The effect of gastric bypass operation on glucose tolerance in obesity. Scand J Gastroenterol Suppl 1985; 107: 24-31. (Pubitemid 15142055)
150. Meryn S, Stein D, Straus EW. Fasting-and meal-stimulated peptide hormone concentrations before and after gastric surgery for morbid obesity. Metabolism 1986; 35: 798-802. (Pubitemid 16025540)
151. Meryn S, Stein D, Straus EW. Pancreatic polypeptide, pancreatic glucagon and enteroglucagon in morbid obesity and following gastric bypass operation. Int J Obes 1986; 10: 37-42. (Pubitemid 16107653)
152. Amland PF, Jorde R, Giercksky KE, Burhol PG. Diurnal GIP, PP and insulin levels in morbid obesity before and after stapled gastric partitioning with gastro-gastrostomy Int J Obes 1984; 8: 117-122. (Pubitemid 14130605)
153. Amland PF, Jorde R, Kildebo S, Burhol PG, Giercksky KE. Effects of a gastric partitioning operation for morbid obesity on the secretion of gastric inhibitory polypeptide and pancreatic polypeptide. Scand J Gastroenterol 1984; 19: 857-861. (Pubitemid 14027541)
154. Civalleri D, Bloom SR, Sarson DL, Gianetta E, Bonalumi U, Friedman D et al. Behavior of plasma pancreatic polypeptides and motilin in obese patients subjected to biliopancreatic bypass]. Boll Soc Ital Biol Sper 1980; 56: 1929-1935. (Pubitemid 11216077)
155. Dubrasquet M, Bataille D, Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor ofpentagastrin-stimulated acid secretion in rats. Biosci Rep 1982; 2: 391-395. (Pubitemid 12064149)
156. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696-4701. (Pubitemid 37357514)
157. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine ofpigs. Regul Pept 1988; 21: 151-166.
158. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001; 142: 4244-4250. (Pubitemid 32907050)
159. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-2695. (Pubitemid 38686215)
160. Strader AD, Vahl TP, Jandacek RJ, Woods SC, D'Alessio DA, Seeley RJ. Weight loss through ileal transposition is accom-panied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005; 288: E447-E453. (Pubitemid 40110655)
161. Barry RE, Barisch J, Bray GA, Sperling MA, Morin RJ, Benfield J. Intestinal adaptation after jejunoileal bypass in man. Am J Clin Nutr 1977; 30: 32-42. (Pubitemid 8034361)
162. Holst JJ, Sorensen TI, Andersen AN, Stadil F, Andersen B, Lauritsen KB et al. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scand J Gastroenterol 1979; 14: 205-207. (Pubitemid 9162978)
163. Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H, Billington CJ et al. Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: a preliminary study. J Surg Res 2007; 142: 295-300. (Pubitemid 47418830)
164. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671-1679. (Pubitemid 38857023)
165. Osawa H, Ochi M, Tabara Y, Kato K, Yamauchi J, Takata Y et al. Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf) 2008; 69: 74-80. (Pubitemid 351847266)
166. Gokce N, Vita JA, McDonnell M, Forse AR, Istfan N, Stoeckl M et al. Effect of medical and surgical weight loss on endothelial vasomotor function in obese patients. Am J Cardiol 2005; 95: 266-268. (Pubitemid 40092098)
167. Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H, Billington CJ et al. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res 2007; 141: 31-39. (Pubitemid 46898439)
168. Bose M, Teixeira J, Olivan B, Scherer PE, Pi-Sunyer FX, Bawa B et al. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes 2010; 2: 47-55.
169. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003; 138: 389-396. (Pubitemid 36417676)
170. Vincent RP, le Roux CW. Changes in gut hormones after bariatric surgery. Clin Endocrinol (Oxf) 2008; 69: 173-179. (Pubitemid 352009012)
171. Sugerman HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg 1987; 205: 613-624. (Pubitemid 17103382)
172. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142: 547-559.
173. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120: 669-681. (Pubitemid 32171639)
174. Nightengale ML, Sarr MG, Kelly KA, Jensen MD, Zinsmeister AR, Palumbo PJ. Prospective evaluation of vertical banded gastroplasty as the primary operation for morbid obesity. Mayo Clin Proc 1991; 66: 773-782.
175. Howard L, Malone M, Michalek A, Carter J, Alger S, Van Woert J. Gastric bypass and vertical banded gastroplasty-a prospective randomized comparison and 5-year follow-up. Obes Surg 1995; 5: 55-60.
176. Naslund I, Wickbom G, Christoffersson E, Agren G. A prospective randomized comparison of gastric bypass and gastroplasty. Com-plications and early results. Acta Chir Scand 1986; 152: 681-689. (Pubitemid 17229162)
177. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA 2002; 288: 2793-2796. (Pubitemid 35425059)
178. Faraj M, Jones P, Sniderman AD, Cianflone K. Enhanced dietary fat clearance in postobese women. J Lipid Res 2001; 42: 571-580. (Pubitemid 32367000)
179. MacLean LD, Rhode BM, Nohr CW. Long-or short-limb gastric bypass? J Gastrointest Surg 2001; 5: 525-530.
180. Naslund I. Gastric bypass versus gastroplasty. A prospective study of differences in two surgical procedures for morbid obesity. Acta Chir Scand Suppl 1987; 536: 1-60.
181. Boza C, Gagner M, Devaud N, Escalona A, Munoz R, Gandarillas M. Laparoscopic sleeve gastrectomy with ileal transposition (SGIT): a new surgical procedure as effective as gastric bypass for weight control in a porcine model. Surg Endosc 2008; 22: 1029-1034.
182. Koopmans HS, Sclafani A, Fichtner C, Aravich PF. The effects of ileal transposition on food intake and body weight loss in VMH-obese rats. Am J Clin Nutr 1982; 35: 284-293. (Pubitemid 12121027)
183. Koopmans HS, Ferri GL, Sarson DL, Polak JM, Bloom SR. The effects of ileal transposition and jejunoileal bypass on food intake and GI hormone levels in rats. Physiol Behav 1984; 33: 601-609. (Pubitemid 15201821)
184. de Paula AL, Macedo AL, Prudente AS, Queiroz L, Schraibman V, Pinus J. Laparoscopic sleeve gastrectomywith ileal interposition ('neuroendocrine brake')\pilot study of a new operation. Surg Obes Relat Dis 2006; 2: 464-467. (Pubitemid 44028838)
185. Gagner M. La transposition ile'ale avec ou sans gastrectomy par laparoscopie chez l'homme (TIG). J Coeliochirurgie 2005; 54: 4-9.
186. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004; 239: 1-11. (Pubitemid 38176365)
187. Stylopoulos N, Hoppin AG, Kaplan LM. Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring) 2009; 17: 1839-1847.
188. Naslund E, Hellstrom PM, Kral JG. The gut and food intake: an update for surgeons. J Gastrointest Surg 2001; 5: 556-567. (Pubitemid 33649520)
189. Flancbaum L, Choban PS, Bradley LR, Burge JC. Changes in measured resting energy expenditure after Roux-en-Y gastric bypass for clinically severe obesity. Surgery 1997; 122: 943-949. (Pubitemid 27495936)
190. Carrasco F, Papapietro K, Csendes A, Salazar G, Echenique C, Lisboa C et al. Changes in resting energy expenditure and body composition after weight loss following Roux-en-Y gastric bypass. Obes Surg 2007; 17: 608-616. (Pubitemid 46945428)
191. de Castro Cesar M, de Lima Montebelo MI, Rasera Jr I, de Oliveira Jr AV, Gomes Gonelli PR, Aparecida Cardoso G. Effects of Roux-en-Y gastric bypass on resting energy expendi-ture in women. Obes Surg 2008; 18: 1376-1380.
192. Xu Y, Ramos EJ, Middleton F, Romanova I, Quinn R, Chen C et al. Gene expression profiles post Roux-en-Y gastric bypass. Surgery 2004; 136: 246-252. (Pubitemid 39037661)
193. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (London) 2009; 33: 786-795.
194. Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. JHepatol 2009; 51: 765-777.
195. Nijhuis J, van Dielen FM, Fouraschen SM, van den Broek MA, Rensen SS, Buurman WA et al. Endothelial activation markers and their key regulators after restrictive bariatric surgery. Obesity (Silver Spring) 2007; 15: 1395-1399. (Pubitemid 47110902)
196. Kopp HP, Krzyzanowska K, Mohlig M, Spranger J, Pfeiffer AF, Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (London) 2005; 29: 766-771. (Pubitemid 40897012)
197. Roth CL, Reinehr T, Schernthaner GH, Kopp HP, Kriwanek S, Schernthaner G. Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. Obes Surg 2009; 19: 29-35.
198. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 2479-2485. (Pubitemid 352008510)
199. Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care 2009; 32: 375-380.
200. Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30: 1709-1716. (Pubitemid 47036341)
201. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004; 70: 1-4; discussion 4-5.